Skip to main content

Table 1 Patient clinicopathological characteristics

From: Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy

Sample ID Age Pre-treatment PSA (ng/ml) Pathological stages Gleason score Risk group based on NCCN guidelines
B15 67 5.4 cT2a cN0 cM0 3 + 4 IR
B16 76 15.8 cT2a cN0 cM0 4 + 3 IR
B17 78 6.3 cT2b cN0 cM0 3 + 4 IR
B03 82 24.4 cT1c cN0 cM0 8 HR
B60 68 17.6 cT2a cN0 M0 3 + 4 IR
C73 66 0.9 pT2a pN0 M0 3 + 4 IR
B09 71 13.30 cT3a cN0 M0 4 + 5 HR
C05 74 0.40 pT3 pN0 M0 3 + 4 HR
C12 67 0.20 pT3a pN0 M0 3 + 4 HR
B71 54 7.2 cT1c cN0 cM0 3 + 3 IR
C59 73 0.8 pT3a pN0 cM0 4 + 4 HR
  1. IR intermediate risk group, HR high risk group, NCCN National Comprehensive Cancer Network